NASDAQ:ONCT • US68236P2065
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Oncternal Therapeutics Inc (ONCT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-09-12 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-09-12 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-04 | Brookline Capital | Upgrade | Hold -> Buy |
| 2023-09-18 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-04-04 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-04-04 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-04-04 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-04-04 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-04-04 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-03-22 | Oppenheimer | Maintains | Outperform |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-22 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-10 | Maxim Group | Initiate | Buy |
| 2022-02-24 | BTIG | Initiate | Buy |
| 2021-04-07 | Oppenheimer | Initiate | Outperform |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.315M 27.85% | 1.49M -65.47% | 785K -47.32% | 1.678M 113.76% | 612K -63.53% | 1.02M 66.67% | 765K -25.00% | 765K | -100.00% | ||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -31.366M -78.81% | -44.947M -43.30% | -41.714M 7.19% | -37.436M 10.26% | -50.388M -34.60% | -58.14M -15.38% | -65.535M -12.72% | -65.535M | -15.559M 76.26% | -6.34M 59.25% | |
| Operating Margin | -726.91% | -3,016.58% | -5,313.89% | -2,230.99% | -8,233.33% | -5,700.00% | -8,566.67% | -8,566.67% | N/A | N/A | |
| EPS YoY % growth | -12.60 37.61% | -16.80 -33.33% | -13.51 19.58% | -12.12 10.27% | -10.46 13.76% | -6.28 39.90% | -5.46 13.15% | -5.34 2.06% | 0.74 113.93% | 1.81 142.47% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.02 2.92% | -2.47 12.78% | -2.23 22.71% | -2.04 28.67% | -2.09 30.74% |
| Revenue Q2Q % growth | 140.25K -52.78% | 204K -64.15% | 204K -74.53% | 204K -58.70% | 204K 45.45% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.343M 3.04% | -11.166M -27.19% | -11.47M -29.41% | -11.73M -35.12% | -12.101M -29.52% |
All data in USD
6 analysts have analysed ONCT and the average price target is 2.04 USD. This implies a price increase of 287.39% is expected in the next year compared to the current price of 0.5266.
The consensus EPS estimate for the next earnings of Oncternal Therapeutics Inc (ONCT) is -3.02 USD and the consensus revenue estimate is 140.25K USD.
The consensus rating for Oncternal Therapeutics Inc (ONCT) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.